Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Feasibility and Efficacy Trial of a Novel Reversible LSD1 Inhibitor SP-2577 (Seclidemstat) Plus Pembrolizumab in Select SWI/SNF-mutant Gynecologic Cancers

NCT04611139 is registered in ClinicalTrials.gov with HonorHealth Research Institute as lead sponsor.

NCT NCT04611139
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04611139 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Feasibility and Efficacy Trial of a Novel Reversible LSD1 Inhibitor SP-2577 (Seclidemstat) Plus Pembrolizumab in Select SWI/SNF-mutant Gynecologic Cancers
Lead sponsor
HonorHealth Research Institute
Phase
Phase 1
Overall status
Withdrawn
Start date
December 31, 2021
Completion date
June 30, 2024
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer, ovarian clear cell tumor, ovarian endometrioid adenocarcinoma, sccoht